BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35978602)

  • 1. Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy.
    Kuroda H; Oikawa T; Ninomiya M; Fujita M; Abe K; Okumoto K; Katsumi T; Sato W; Igarashi G; Iino C; Endo T; Tanabe N; Numao H; Fukuda S; Iijima K; Masamune A; Ohira H; Ueno Y; Takikawa Y
    Liver Cancer; 2022 Jul; 11(4):383-396. PubMed ID: 35978602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
    Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study.
    Sun B; Zhang L; Sun T; Ren Y; Cao Y; Zhang W; Zhu L; Guo Y; Gui Y; Liu F; Chen L; Xiong F; Zheng C
    Front Oncol; 2022; 12():982948. PubMed ID: 36172158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
    Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
    J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
    Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
    Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effect of Lenvatinib Re-Administration after Transcatheter Arterial Chemoembolization in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Mawatari S; Tamai T; Kumagai K; Saisyoji A; Muromachi K; Toyodome A; Taniyama O; Sakae H; Ijuin S; Tabu K; Oda K; Hiramine Y; Moriuchi A; Sakurai K; Kanmura S; Ido A
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study.
    Oshita K; Kobayashi T; Namba Y; Fukuhara S; Matsubara K; Takei D; Nakano R; Okamoto W; Sakai H; Tanimine N; Nakahara T; Kuroda S; Tahara H; Ohira M; Kawaoka T; Ide K; Imamura M; Aikata H; Ohdan H
    BMJ Open; 2023 Oct; 13(10):e073797. PubMed ID: 37798025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Lenvatinib's Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma.
    Amioka K; Kawaoka T; Kinami T; Yamasaki S; Kosaka M; Johira Y; Yano S; Naruto K; Ando Y; Fujii Y; Uchikawa S; Ono A; Yamauchi M; Imamura M; Kosaka Y; Ohya K; Mori N; Takaki S; Tsuji K; Masaki K; Honda Y; Kouno H; Kohno H; Morio K; Moriya T; Naeshiro N; Nonaka M; Aisaka Y; Azakami T; Hiramatsu A; Aikata H; Oka S
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
    Shimose S; Iwamoto H; Niizeki T; Tanaka M; Shirono T; Moriyama E; Noda Y; Nakano M; Suga H; Kuromatsu R; Torimura T; Koga H; Kawaguchi T
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
    Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
    Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
    Acad Radiol; 2024 May; ():. PubMed ID: 38760273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
    Peng Z; Fan W; Zhu B; Wang G; Sun J; Xiao C; Huang F; Tang R; Cheng Y; Huang Z; Liang Y; Fan H; Qiao L; Li F; Zhuang W; Peng B; Wang J; Li J; Kuang M
    J Clin Oncol; 2023 Jan; 41(1):117-127. PubMed ID: 35921605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma.
    Liu J; Yan S; Zhang G; Yang L; Wei S; Yi P
    Oncol Lett; 2023 Dec; 26(6):507. PubMed ID: 37920437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.